PE20000269A1 - Polisacaridos de sintesis, procedimiento para su preparacion y composiciones farmaceuticas que los contienen - Google Patents

Polisacaridos de sintesis, procedimiento para su preparacion y composiciones farmaceuticas que los contienen

Info

Publication number
PE20000269A1
PE20000269A1 PE1999000044A PE00004499A PE20000269A1 PE 20000269 A1 PE20000269 A1 PE 20000269A1 PE 1999000044 A PE1999000044 A PE 1999000044A PE 00004499 A PE00004499 A PE 00004499A PE 20000269 A1 PE20000269 A1 PE 20000269A1
Authority
PE
Peru
Prior art keywords
glucopyranosil
methyl
sulfo
tri
polysaccharides
Prior art date
Application number
PE1999000044A
Other languages
English (en)
Inventor
Van Boeckel Constant
Dreef-Tromp Cornelia
Herbert Jean-Marc
Alexandre Driguez Pierre
Petitou Maurice
Duchaussoy Philippe
Basten Johannes
Original Assignee
Sanofi Sa
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa, Akzo Nobel Nv filed Critical Sanofi Sa
Publication of PE20000269A1 publication Critical patent/PE20000269A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A POLISACARIDOS DE SINTESIS EN FORMA DE ACIDO, UTILIZANDOSE DE 0,1 mg A 100 mg. SON COMPUESTOS PREFERIDOS: METIL-O-(2,3,4,6-TETRA-O-SULFO-O-D-GLUCOPIRANOSIL)-(1 4)-O-(2,3,6-TRI-O-SULFO-O-D-GLUCOPIRANOSIL)-(1 4)-O-(2,3,6-TRI-O-SULFO-ß-D-GLUCOPIRANOSIL)-(1 4)-O-(2,3-DI-O-METIL-6-O-SULFO-O-D-GLUCOPIRANOSIL)-(1 4)-O-(2,3,6-TRI-O-METIL-ß-D-GLUCOPIRANOSIL)-(1 4)-[O-(2,3,6-TRI-O-METIL-O-D-GLUCOPIRANOSIL)-(1 4)-O-(2,3,6-TRI-O-METIL-ß-D-GLUCOPIRANOSIL)-(1 4)]3-O-(2,3-DI-O-METIL-6-O-SULFO-O-D-GLUCOPIRANOSIL)-(1 4)-O-(ACIDO-2,3-DI-O-METIL-ß-D-GLUCOPIRANOSILURONICO)-(1 4)-O-(2,3,6-TRI-O-SULFO-O-D-GLUCOPIRANOSIL)-(1 4)-O-ACIDO-2,3-DI-O-METIL-O-L-IDOPIRANOSILURONICO)-(1 4)-3-O-METIL-2,6-DI-O-SULFO-O-D-GLUCOPIRANOSIDO. EL POLISACARIDO ACTUA COMO ANTICOAGULANTE Y ANTITROMBOTICO DE HEPARINA Y PUEDE SER UTIL PARA EL TRATAMIENTO Y PREVENCION DE TRASTORNOS DEL SISTEMA CARDIOVASCULAR Y CEREBROVASCULAR, TRASTORNOS TROMBOEMBOLICOS ASOCIADOS A ATEROSCLEROSIS, DIABETES, RETROMBOSIS LUEGO DE UNA TROMBOLISIS, INFARTO
PE1999000044A 1998-01-19 1999-01-19 Polisacaridos de sintesis, procedimiento para su preparacion y composiciones farmaceuticas que los contienen PE20000269A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9800515A FR2773804B1 (fr) 1998-01-19 1998-01-19 Polysaccharides de synthese, procede pour leur preparation et compositions pharmaceutiques le contenant

Publications (1)

Publication Number Publication Date
PE20000269A1 true PE20000269A1 (es) 2000-06-15

Family

ID=9521914

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999000044A PE20000269A1 (es) 1998-01-19 1999-01-19 Polisacaridos de sintesis, procedimiento para su preparacion y composiciones farmaceuticas que los contienen

Country Status (41)

Country Link
US (1) US6528497B1 (es)
EP (1) EP1049721B1 (es)
JP (1) JP4402835B2 (es)
KR (1) KR100513196B1 (es)
CN (1) CN1165550C (es)
AR (1) AR013019A1 (es)
AT (1) ATE209219T1 (es)
AU (1) AU741748B2 (es)
BR (1) BRPI9907025B8 (es)
CA (1) CA2317465C (es)
CO (1) CO4970795A1 (es)
CZ (1) CZ297815B6 (es)
DE (1) DE69900718T2 (es)
DK (1) DK1049721T3 (es)
DZ (1) DZ2709A1 (es)
EE (1) EE04157B1 (es)
EG (1) EG23982A (es)
ES (1) ES2168000T3 (es)
FR (1) FR2773804B1 (es)
GT (1) GT199900003A (es)
HK (1) HK1030002A1 (es)
HR (1) HRP20000480B1 (es)
HU (1) HU228333B1 (es)
IL (1) IL137241A0 (es)
MA (1) MA26597A1 (es)
MY (1) MY119090A (es)
NO (1) NO329903B1 (es)
NZ (1) NZ505492A (es)
PE (1) PE20000269A1 (es)
PL (1) PL202802B1 (es)
PT (1) PT1049721E (es)
RU (1) RU2211224C2 (es)
SA (1) SA99191113B1 (es)
SI (1) SI1049721T1 (es)
SK (1) SK283411B6 (es)
TR (1) TR200002078T2 (es)
TW (1) TW548279B (es)
UA (1) UA60352C2 (es)
UY (1) UY25356A1 (es)
WO (1) WO1999036443A1 (es)
ZA (1) ZA99355B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2814463B1 (fr) * 2000-09-22 2002-11-15 Sanofi Synthelabo Nouveaux polysaccharides a activite antithrombotique comprenant au moins une liaison covalente avec la biotine ou un derive de la biotine
FR2874924B1 (fr) 2004-09-09 2006-12-01 Sanofi Aventis Sa Hexadecasaccharides biotinyles, leur preparation et leur utilisation therapeutique
TWI403334B (zh) 2004-12-23 2013-08-01 Merck Sharp & Dohme 包含生物素殘基之抗血栓雙重抑制劑
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
IL188647A0 (en) 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
WO2009130704A1 (en) * 2008-04-24 2009-10-29 Technion Research And Development Foundation Ltd. Beta-lactoglobulin-polysaccharide nanoparticles for hydrophobic bioactive compounds
KR101529061B1 (ko) 2008-05-30 2015-06-16 모멘타 파머슈티컬스 인코포레이티드 당류 구조물, 그리고 이러한 구조물의 제조 및 사용 방법
FR2935386B1 (fr) * 2008-08-26 2010-09-10 Sanofi Aventis Nouveaux polysaccharides a activite antithrombotique comprenant une liaion covalente avec une chaine amine
WO2010117803A2 (en) * 2009-03-30 2010-10-14 University Of Georgia Research Foundation, Inc. Heparan sulfate synthesis
EP2451442A4 (en) 2009-07-09 2014-02-12 Oshadi Drug Administration Ltd MATRIX COMPOSITION COMPOSITIONS, METHODS AND USES
US8288515B2 (en) 2009-07-31 2012-10-16 Reliable Biopharmaceutical Corporation Process for preparing Fondaparinux sodium and intermediates useful in the synthesis thereof
FR2949114B1 (fr) 2009-08-14 2011-08-26 Sanofi Aventis OCTASACCHARIDES N-ACYLES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
FR2949115B1 (fr) 2009-08-14 2012-11-02 Sanofi Aventis OLIGOSACCHARIDES N-SULFATES ACTIVATEURS DES RECEPTEURS DES FGFs, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
US8420790B2 (en) 2009-10-30 2013-04-16 Reliable Biopharmaceutical Corporation Efficient and scalable process for the manufacture of Fondaparinux sodium
EP2614089A1 (fr) 2010-09-10 2013-07-17 Sanofi-Aventis Polysaccharides biotinyles a activite antithrombotique et presentant une stabilite metabolique amelioree
US9005664B2 (en) 2010-10-17 2015-04-14 Technion Research And Development Foundation Ltd. Denatured lactoglobulin and polyphenol coassemblies
FR2970969B1 (fr) 2011-01-27 2013-10-18 Sanofi Aventis Oligosaccharides 3-o-alkyles activateurs des recepteurs des fgfs, leur preparation et leur application en therapeutique

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ260933A (en) * 1993-07-16 1996-07-26 Hercules Inc Cation-complexed polysaccharides; use in foods and pharmaceuticals
FR2749849B1 (fr) * 1996-06-14 1998-09-04 Sanofi Sa Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant
CZ427499A3 (cs) * 1998-05-29 2000-05-17 The Procter & Gamble Company Jemné topické antimikrobiální přípravky

Also Published As

Publication number Publication date
DZ2709A1 (fr) 2003-09-01
ES2168000T3 (es) 2002-05-16
BR9907025B1 (pt) 2013-12-10
NZ505492A (en) 2001-12-21
DE69900718T2 (de) 2002-08-22
FR2773804A1 (fr) 1999-07-23
CN1288470A (zh) 2001-03-21
ATE209219T1 (de) 2001-12-15
ZA99355B (en) 2000-10-11
DK1049721T3 (da) 2002-04-02
TR200002078T2 (tr) 2000-11-21
EE200000429A1 (et) 2003-06-16
PL341875A1 (en) 2001-05-07
CZ20002635A3 (cs) 2000-12-13
EE04157B1 (et) 2003-10-15
SA99191113B1 (ar) 2006-10-11
AR013019A1 (es) 2000-11-22
BR9907025A (pt) 2000-10-17
NO20003662D0 (no) 2000-07-17
PL202802B1 (pl) 2009-07-31
EP1049721B1 (fr) 2001-11-21
CZ297815B6 (cs) 2007-04-04
EP1049721A1 (fr) 2000-11-08
HK1030002A1 (en) 2001-04-20
HRP20000480A2 (en) 2000-12-31
CA2317465C (en) 2008-05-20
NO20003662L (no) 2000-09-14
AU1974599A (en) 1999-08-02
PT1049721E (pt) 2002-05-31
US6528497B1 (en) 2003-03-04
TW548279B (en) 2003-08-21
EE200000429A (et) 2001-12-17
KR20010034189A (ko) 2001-04-25
IL137241A0 (en) 2001-07-24
SI1049721T1 (en) 2002-06-30
EG23982A (en) 2008-02-27
RU2211224C2 (ru) 2003-08-27
WO1999036443A1 (fr) 1999-07-22
UY25356A1 (es) 2000-10-31
NO329903B1 (no) 2011-01-24
CA2317465A1 (en) 1999-07-22
GT199900003A (es) 2000-07-07
CO4970795A1 (es) 2000-11-07
DE69900718D1 (de) 2002-02-21
FR2773804B1 (fr) 2000-02-18
KR100513196B1 (ko) 2005-09-07
HRP20000480B1 (en) 2002-04-30
HU228333B1 (en) 2013-03-28
JP4402835B2 (ja) 2010-01-20
MA26597A1 (fr) 2004-12-20
SK10782000A3 (sk) 2001-02-12
SK283411B6 (sk) 2003-07-01
CN1165550C (zh) 2004-09-08
UA60352C2 (uk) 2003-10-15
MY119090A (en) 2005-03-31
HUP0102009A3 (en) 2003-07-28
AU741748B2 (en) 2001-12-06
JP2002509164A (ja) 2002-03-26
BRPI9907025B8 (pt) 2016-09-13
HUP0102009A1 (hu) 2001-11-28

Similar Documents

Publication Publication Date Title
PE20000269A1 (es) Polisacaridos de sintesis, procedimiento para su preparacion y composiciones farmaceuticas que los contienen
Yoon et al. The nontoxic mushroom Auricularia auricula contains a polysaccharide with anticoagulant activity mediated by antithrombin
Jouault et al. Characterization, chemical modifications and in vitro anticoagulant properties of an exopolysaccharide produced by Alteromonas infernus
DE60130669T2 (de) Polysaccharide mit antithrombotischer wirkung, die mit biotin oder einem biotinderivat kovalent gebunden sind
Barrowcliffe et al. Low-affinity heparin potentiates the action of high-affinity heparin oligosaccharides
Nahain et al. Heparin mimetics with anticoagulant activity
Yamada et al. Structural characterisation of an anti-complementary pectic polysaccharide from the roots of Bupleurum falcatum L.
BR0111126A (pt) Derivados de aminoácidos cìclicos úteis como agentes farmacêuticos
Šoltés et al. Degradation of high-molar-mass hyaluronan and characterization of fragments
ATE26281T1 (de) Depolymerisiertes und supersulfatiertes heparin, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zusammensetzungen.
DZ3402A1 (fr) Cyclopentanoindoles, compositions contenant ces composes et methodes de traitement
BR0007781A (pt) Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf
BRPI0611872B8 (pt) reagente polimérico, conjugado, método para preparação de um conjugado e composição farmacêutica
BR0112612A (pt) Misturas de polissacarìdeos sulfatados, processo de preparação das mesmas e composições farmacêuticas
ATE277929T1 (de) Immunsuppressive wirkungen von pteridinderivaten
DE69526854D1 (de) Physikalisch modifizierte abbaubare thermoplastische zusammensetzung
OA09558A (fr) Compositions a base de proanthocyanidols leur application pharmacologique
Pawlaczyk et al. An acidic glycoconjugate from Lythrum salicaria L. with controversial effects on haemostasis
CO5440227A1 (es) Composicion antihelmitica e inyectable mejorada de crecimiento
Ishii Enzymatic extraction and linkage analysis of pectic polysaccharides from onion
ECSP066305A (es) Mezclas de oligosacáridos derivados de la heparina, su preparación y las composiciones farmacéuticas que las contienen
AR018142A1 (es) Composicion para el cabello que tiene un ph superior a 10 y comprende uno o mas derivados cationicos de goma guar
de Oliveira Barddal et al. Anticoagulant activity of native and partially degraded glycoglucuronomannan after chemical sulfation
EP3063177B1 (en) Derivatives of n-desulfated glycosaminoglycans and use as drugs
ES2088780T3 (es) Complejos de inclusion con silibinina, su preparacion y composiciones farmaceuticas que los contienen.

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed